Insights into breast cancer phenotying through molecular omics approaches and therapy response

Area of Science:

• Oncology
• Genomics
• Bioinformatics

Background:

• Breast cancer is the most common malignancy globally, with ~30% of early-stage cases progressing to metastasis despite diagnostic advancements.
• Distinct molecular subtypes of breast cancer exhibit variable responses to therapies, and tumor heterogeneity often drives treatment resistance.
• Current therapeutic strategies require refinement to improve efficacy and minimize toxicity, particularly for heterogeneous tumors.

Purpose of the Study:

• To review integrative omics approaches and computational analyses for understanding breast cancer heterogeneity.
• To highlight how these methods provide insights into molecular differences across breast cancer subtypes.
• To demonstrate the clinical relevance of these approaches in predicting patient response to therapies.

Main Methods:

• Integrative omics approaches including genome, epigenome, transcriptome, and immune profiling.
• Application of mathematical and computational analyses to interpret complex biological data.
• Examination of intratumoral heterogeneity in the context of clinical and molecular characteristics.

Main Results:

• Integrative omics combined with computational analysis can elucidate mechanistic insights into breast cancer subtypes.
• These approaches offer a deeper understanding of the molecular drivers of treatment response and resistance.
• Identification of key differences in breast cancer subtypes and their implications for therapy selection.

Conclusions:

• Integrative omics and computational methods are crucial for dissecting breast cancer heterogeneity.
• These advanced analyses provide clinically relevant insights for personalized treatment strategies.
• Further investigation into these technologies promises to enhance breast cancer treatment efficacy and reduce toxicity.